<DOC>
	<DOCNO>NCT02064309</DOCNO>
	<brief_summary>The primary objective clinical investigation investigate safety implantation human islet contain device Beta-Air type 1 diabetic subject . The secondary objective clinical investigation investigate transplantation macro-encapsulated human islet within Beta-Air device provide improve glycaemic control type 1 diabetes patient reduced incidence hypoglycaemic episode .</brief_summary>
	<brief_title>An Open Label , Pilot Investigation , Assess Safety Efficacy Transplantation Macro-encapsulated Human Islets Within Bioartificial Pancreas Beta-Air Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>1 . Informed consent obtain investigationrelated activity . Investigationrelated activity procedure would perform normal management subject . 2 . Diagnosis type 1 diabetes mellitus &gt; 5 year 3 . Men woman &gt; 18 year age time enrolment 4 . Involvement intensive diabetes management define selfmonitoring blood glucose level less mean three time per day average week administration three insulin injection per day insulin pump therapy . This management must direction diabetologist diabetes specialist 12 month prior study enrolment . 1 . Body mass index ( BMI ) &gt; 30 kg/mÂ² 2 . Insulin requirement &gt; 1.0 Units/kg/day 3 . HbA1c &gt; 10 % ( DCCT ) 4 . Random Cpeptide &gt; 0.003 nmol/l 5 . Known untreated active proliferative diabetic retinopathy change increase macular oedema 6 . Renal failure ( Glomerular Filtration Rate &lt; 60 ml/min ) 7 . Women childbearing potential pregnant , breastfeed intend become pregnant unwilling use adequate contraceptive method duration trial ( implant , injectables , combine oral contraceptive , hormonal intrauterine device , sexual abstinence vasectomise partner ) . 8 . Active infection include hepatitis B , hepatitis C , HIV , Tbc 9 . Any history malignancy except completely resect squamous basal cell carcinoma skin 10 . Known active alcohol drug abuse . 11 . Any coagulopathy medical condition would require longterm anticoagulant therapy ( e.g. , Warfarin ) transplantation ( lowdose aspirin treatment allow ) subject international normalized ratio ( INR ) &gt; 1.5 . 12 . Severe coexist cardiac disease , characterized condition : 1 . Recent myocardial infarction ( within past 36 week ) 2 . Evidence ischemia functional cardiac exam within last year 3 . Left ventricular ejection fraction &lt; 30 % 4 . Cardiovascular condition within 36 week prior trial : i. Decompensated heart failure New York Heart Association ( NYHA ) class III IV ii . Unstable angina pectoris iii . Coronary arterial bypass graft iv . Coronary angioplasty 13 . Inadequately treat blood pressure elevation ( systolic BP &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg ) 14 . Use medication treat diabetes insulin within 4 week enrolment 15 . Administration live attenuate vaccine ( ) within 8 week enrolment 16 . Any previous organ transplant 17 . Treatment immunosuppressive drug 18 . Any medical condition , opinion investigator , interfere safe participation trial ( e.g. , systemic glucocorticoid ) 19 . Known suspected allergy hypersensitivity trial product ( ) relate product 20 . The receipt investigational product within 30 day screen trial 21 . Any scheduled transplant addition islet transplantation 22 . Fulfillment criterion clinical pancreas islet transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>